Literature DB >> 20631129

TLR4 ligands augment antigen-specific CD8+ T lymphocyte responses elicited by a viral vaccine vector.

Elizabeth G Rhee1, R Phelps Kelley, Isha Agarwal, Diana M Lynch, Annalena La Porte, Nathaniel L Simmons, Sarah L Clark, Dan H Barouch.   

Abstract

Toll-like receptor (TLR) ligands are critical activators of innate immunity and are being developed as vaccine adjuvants. However, their utility in conjunction with viral vector-based vaccines remains unclear. In this study, we evaluated the impact of a variety of TLR ligands on antigen-specific CD8(+) T lymphocyte responses elicited by a recombinant adenovirus serotype 26 (rAd26) vector expressing simian immunodeficiency virus Gag in mice. The TLR3 ligand poly(I:C) suppressed Gag-specific cellular immune responses, whereas the TLR4 ligands lipopolysaccharide and monophosphoryl lipid A substantially augmented the magnitude and functionality of these responses by a MyD88- and TRIF-dependent mechanism. These data demonstrate that TLR ligands can modulate the immunogenicity of viral vaccine vectors both positively and negatively. Moreover, these findings suggest the potential utility of TLR4 ligands as adjuvants for rAd vector-based vaccines.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20631129      PMCID: PMC2937821          DOI: 10.1128/JVI.00928-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  42 in total

1.  The repertoire for pattern recognition of pathogens by the innate immune system is defined by cooperation between toll-like receptors.

Authors:  A Ozinsky; D M Underhill; J D Fontenot; A M Hajjar; K D Smith; C B Wilson; L Schroeder; A Aderem
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

Review 2.  Role of Toll-like receptors in costimulating cytotoxic T cell responses.

Authors:  Katrin Schwarz; Tazio Storni; Vania Manolova; Arnaud Didierlaurent; Jean-Claude Sirard; Peter Röthlisberger; Martin F Bachmann
Journal:  Eur J Immunol       Date:  2003-06       Impact factor: 5.532

3.  Route of adenovirus-based HIV-1 vaccine delivery impacts the phenotype and trafficking of vaccine-elicited CD8+ T lymphocytes.

Authors:  David R Kaufman; Maytal Bivas-Benita; Nathaniel L Simmons; Darby Miller; Dan H Barouch
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

4.  Using 3 TLR ligands as a combination adjuvant induces qualitative changes in T cell responses needed for antiviral protection in mice.

Authors:  Qing Zhu; Colt Egelston; Susan Gagnon; Yongjun Sui; Igor M Belyakov; Dennis M Klinman; Jay A Berzofsky
Journal:  J Clin Invest       Date:  2010-01-25       Impact factor: 14.808

5.  Surface-expressed TLR6 participates in the recognition of diacylated lipopeptide and peptidoglycan in human cells.

Authors:  Yoshiya Nakao; Kenji Funami; Satomi Kikkawa; Mitsue Taniguchi; Miyuki Nishiguchi; Yasuhiro Fukumori; Tsukasa Seya; Misako Matsumoto
Journal:  J Immunol       Date:  2005-02-01       Impact factor: 5.422

Review 6.  Taking toll: lipid A mimetics as adjuvants and immunomodulators.

Authors:  David H Persing; Rhea N Coler; Michael J Lacy; David A Johnson; Jory R Baldridge; Robert M Hershberg; Steven G Reed
Journal:  Trends Microbiol       Date:  2002       Impact factor: 17.079

7.  Toll-like receptor 6-independent signaling by diacylated lipopeptides.

Authors:  Ute Buwitt-Beckmann; Holger Heine; Karl-Heinz Wiesmüller; Günther Jung; Roland Brock; Shizuo Akira; Artur J Ulmer
Journal:  Eur J Immunol       Date:  2005-01       Impact factor: 5.532

8.  Cutting edge: polyinosinic:polycytidylic acid boosts the generation of memory CD8 T cells through melanoma differentiation-associated protein 5 expressed in stromal cells.

Authors:  Yaming Wang; Marina Cella; Susan Gilfillan; Marco Colonna
Journal:  J Immunol       Date:  2010-02-17       Impact factor: 5.422

9.  Phenotypic analysis of antigen-specific T lymphocytes.

Authors:  J D Altman; P A Moss; P J Goulder; D H Barouch; M G McHeyzer-Williams; J I Bell; A J McMichael; M M Davis
Journal:  Science       Date:  1996-10-04       Impact factor: 47.728

10.  Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity.

Authors:  Dan H Barouch; Maria G Pau; Jerome H H V Custers; Wouter Koudstaal; Stefan Kostense; Menzo J E Havenga; Diana M Truitt; Shawn M Sumida; Michael G Kishko; Janelle C Arthur; Birgit Korioth-Schmitz; Michael H Newberg; Darci A Gorgone; Michelle A Lifton; Dennis L Panicali; Gary J Nabel; Norman L Letvin; Jaap Goudsmit
Journal:  J Immunol       Date:  2004-05-15       Impact factor: 5.422

View more
  19 in total

1.  Gene expression profiles identify both MyD88-independent and MyD88-dependent pathways involved in the maturation of dendritic cells mediated by heparan sulfate: a novel adjuvant.

Authors:  Meini Wu; Haixuan Wang; Jiandong Shi; Jing Sun; Zhiqing Duan; Yanhan Li; Jianfang Li; Ningzhu Hu; Yiju Wei; Yang Chen; Yunzhang Hu
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

2.  Combining Monophosphoryl Lipid A (MPL), CpG Oligodeoxynucleotide (ODN), and QS-21 Adjuvants Induces Strong and Persistent Functional Antibodies and T Cell Responses against Cell-Traversal Protein for Ookinetes and Sporozoites (CelTOS) of Plasmodium falciparum in BALB/c Mice.

Authors:  Sakineh Pirahmadi; Sedigheh Zakeri; Akram A Mehrizi; Navid D Djadid; Abbas-Ali Raz; Jafar J Sani
Journal:  Infect Immun       Date:  2019-05-21       Impact factor: 3.441

3.  Toll-like receptor 4 (TLR4) is essential for Hsp70-like protein 1 (HSP70L1) to activate dendritic cells and induce Th1 response.

Authors:  Hongliang Fang; Yanfeng Wu; Xiaohui Huang; Wenying Wang; Bing Ang; Xuetao Cao; Tao Wan
Journal:  J Biol Chem       Date:  2011-07-05       Impact factor: 5.157

4.  Vaccine adjuvants CpG (oligodeoxynucleotides ODNs), MPL (3-O-deacylated monophosphoryl lipid A) and naloxone-enhanced Th1 immune response to the Plasmodium vivax recombinant thrombospondin-related adhesive protein (TRAP) in mice.

Authors:  Saeed Nazeri; Sedigheh Zakeri; Akram A Mehrizi; Navid D Djadid; Georges Snounou; Chiara Andolina; François Nosten
Journal:  Med Microbiol Immunol       Date:  2018-06-09       Impact factor: 3.402

Review 5.  Towards Innovative Design and Application of Recombinant Eimeria as a Vaccine Vector.

Authors:  Xinming Tang; Xianyong Liu; Xun Suo
Journal:  Infect Immun       Date:  2020-04-20       Impact factor: 3.441

6.  Dissociation of TRIF bias and adjuvanticity.

Authors:  Katharina Richard; Darren J Perkins; Erin M Harberts; Yang Song; Archana Gopalakrishnan; Kari Ann Shirey; Wendy Lai; Alexandra Vlk; Anup Mahurkar; Shreeram Nallar; Lynn D Hawkins; Robert K Ernst; Stefanie N Vogel
Journal:  Vaccine       Date:  2020-05-07       Impact factor: 3.641

7.  Evaluation of the immunogenicity and protective efficacy of killed Leishmania donovani antigen along with different adjuvants against experimental visceral leishmaniasis.

Authors:  Ankita Thakur; Harpreet Kaur; Sukhbir Kaur
Journal:  Med Microbiol Immunol       Date:  2014-11-29       Impact factor: 3.402

8.  Toll-like receptor 4 signalling regulates antibody response to adenoviral vector-based vaccines by imprinting germinal centre quality.

Authors:  Ruihua Li; Ju Liu; Shipo Wu; Xiaodong Zai; Yaohui Li; Qiaoling Yang; Lihua Hou; Junjie Xu; Wei Chen
Journal:  Immunology       Date:  2018-06-25       Impact factor: 7.397

9.  MyD88 and TRIF synergistic interaction is required for TH1-cell polarization with a synthetic TLR4 agonist adjuvant.

Authors:  Mark T Orr; Malcolm S Duthie; Hillarie Plessner Windish; Elyse A Lucas; Jeffrey A Guderian; Thomas E Hudson; Narek Shaverdian; Joanne O'Donnell; Anthony L Desbien; Steven G Reed; Rhea N Coler
Journal:  Eur J Immunol       Date:  2013-07-03       Impact factor: 5.532

10.  Fusion of HCV nonstructural antigen to MHC class II-associated invariant chain enhances T-cell responses induced by vectored vaccines in nonhuman primates.

Authors:  Stefania Capone; Mariarosaria Naddeo; Anna Morena D'Alise; Adele Abbate; Fabiana Grazioli; Annunziata Del Gaudio; Mariarosaria Del Sorbo; Maria Luisa Esposito; Virginia Ammendola; Gemma Perretta; Alessandra Taglioni; Stefano Colloca; Alfredo Nicosia; Riccardo Cortese; Antonella Folgori
Journal:  Mol Ther       Date:  2014-01-30       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.